Updates are available Correction dated 2025-02-14

Article History

Accepted: 29 December 2024

First Online: 23 January 2025

Change Date: 10 February 2025

Change Type: Update

Change Details: The original online version of this article was revised. Due to a typesetting mistake, the conclusion included in the structured abstract was incorrect. The correct conclusion reads as follows: "The study provides valuable insights into the negotiation outcomes for medicines with multiple therapeutic indications, particularly in onco-hematologic and immunosuppressive areas. The analysis revealed that additional discounts for EoIs averaged 12.5%, with a median of 11%, a value used to assess the impact of specific determinants. A discount higher than 11% was statistically correlated with drugs having more than five indications and oncology treatments, showing their influence in negotiations. However, the savings from discounts were modest relative to the increased drug spending as more indications were approved. This suggests an imbalance between the cost control achieved through discounts and the rising expenditure due to expanded drug use".

Change Date: 14 February 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s41669-025-00566-2

Declarations

:

: No funds, grants, or other support was received.

: The authors have no competing interests to declare that are relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: The datasets generated and/or analyzed during the current study are not publicly available

: All authors contributed to the study conception and design, material preparation, and data collection. Statistical analyses were performed by E.A. All the authors have read and approved the final version of the manuscript. All the authors wrote and revised the manuscript.